avastin
Roche to challenge FDA on Avastin
December 21, 2010Sales and Marketing EMA, FDA, Roche, avastin, bevacizumab, breast cancer
Roche is set to challenge the decision by the FDA to remove a breast cancer indication from its blockbuster drug …
NICE no for Avastin in breast cancer
December 8, 2010Sales and Marketing NICE, Roche, avastin, bevacizumab, breast cancer, health technology assessment, hta
NICE has refused to back Roche’s Avastin for use in breast cancer patients citing the blockbuster drug’s high cost and …
Bayer’s challenger to Lucentis shows promise
November 22, 2010Research and Development, Sales and Marketing Bayer, Lucentis, Novartis, Regeneron, Roche, VEGF Trap-Eye, age-related macular degeneration, avastin, wet AMD
Phase III data for a new age-related macular degeneration (wet AMD) treatment show it is as good as Lucentis, the …
Roche set to cut 4,800 jobs worldwide
November 17, 2010Manufacturing and Production, Research and Development, Sales and Marketing Jobs, Roche, avastin, cuts, taspoglutide
Roche’s ‘Operational Excellence’ programme will see it cut 6% of its global workforce over the next two years. The initiative …
NICE stands firm on Avastin rejection
November 12, 2010Sales and Marketing NICE, Roche, avastin, bevacizumab, colon cancer, metastatic colorectal cancer, patient access scheme
NICE has refused to recommend Roche’s blockbuster cancer drug Avastin for the treatment of metastatic colorectal cancer in its final …
Avastin patient access scheme too complicated, says NICE
August 25, 2010Sales and Marketing NICE, avastin, patient access
NICE is set to say no again to Avastin for use in patients with colorectal cancer. Avastin was first launched …
FDA advised to halt Avastin breast cancer use
July 21, 2010Sales and Marketing Roche, avastin
In a hammer blow to Roche, an influential Food and Drug Administration vote has gone against its cancer drug Avastin. …
Ovarian cancer trial boost for Avastin
July 5, 2010Research and Development Roche, avastin, ovarian cancer
Roche’s blockbuster oncology drug Avastin has met its primary endpoint of improving progression-free survival in women with ovarian cancer in …
Avastin will remain gold standard for lung cancer to 2018
June 20, 2010Decision Resources, NSCLC, Roche drug tipped to remain key to treatment, avastin
Industry analysts Decision Resources believes that Roche’s Avastin plus chemotherapy agents will remain as the gold standard for the treatment …
Avastin promising in ovarian cancer
June 7, 2010Research and Development ASCO, avastin
Roche’s Avastin took a step closer to winning an additional indication after phase III trial data showed the blockbuster cancer …
Avastin study in ovarian cancer meets primary endpoint
February 25, 2010Research and Development Cancer, avastin, ovarian
Preliminary results from a trial of Roche’s Avastin in advanced ovarian cancer suggest that the drug lengthens progression-free survival when …
Avastin fails in phase III study
February 24, 2010Research and Development Roche, avastin, gastric cancer, stomach cancer
Roche’s Avastin does not help patients with a severe form of stomach cancer to live longer, according to the results …
Avastin shows promise in advanced breast cancer
August 20, 2009Research and Development, Sales and Marketing Roche, avastin, breast cancer
Avastin's rise continues as new data suggests it improves progression-free survival as a second line treatment for advanced breast cancer.The …
Avastin gets US approval in kidney cancer
August 4, 2009Research and Development, Sales and Marketing Roche, US, avastin
Roche's rising star Avastin has won US approval to treat the most common type of kidney cancer, the latest in …
Avastin approved for aggressive brain tumour
May 7, 2009Sales and Marketing GBM, avastin
Roche has gained US approval for Avastin in people with the aggressive brain cancer glioblastoma multiforme (GBM). The drug can …
Latest content
Five Facts about cardiovascular disease
